Akanda Corp., through its subsidiaries, engages in the cultivation, manufacture, and distribution of cannabis products in the United Kingdom, Lesotho, and inter…
$0.84-1.40%
报价 2026-11-06
市值
$2M
EV
$13.9M
PE (TTM)
–
预期 PE
–
52 周区间距高点 -98.5%
$0.84$57.09
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
market cap below $300M floor
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
同行业市值相近 · Drug Manufacturers - Specialty & Generic| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| AKANAkanda Corp. | $2M | -1.4% | – | -160.1% | – | – | – | |
| SBFMSunshine Biopharma, Inc. | $5.8M | -2.9% | – | 29.8% | – | – | – | |
| SNOASonoma Pharmaceuticals, Inc. | $5.3M | +3.7% | +15.5% | 38.9% | – | – | – | |
| YCBDcbdMD, Inc. | $4.7M | +7.2% | +7.1% | 54.7% | – | – | – | |
| APUSApimeds Pharmaceuticals US, Inc | $4.1M | -0.9% | – | 0% | – | – | – | |
| GELSGelteq Limited Ordinary Shares | $4M | -3.4% | – | 100% | – | – | – | |
| RDHLRedHill Biopharma Ltd. | $1.3M | +0.4% | – | 100% | – | – | – | |
| UPCUniverse Pharmaceuticals Inc. | $878,148 | -0.7% | – | 35.9% | – | – | – | |
| IMCCIM Cannabis Corp. | $385,302 | +7.5% | – | 19.8% | – | 47.8x | 4.3x | |
| 同行中位数 | – | – | +11.3% | 37.4% | – | 47.8x | 4.3x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
| Metric | 2026-06-30 Q2 2026 | 2025-12-31 Q4 2025 | 2025-06-30 Q2 2025 | 2024-12-31 Q4 2024 | 2024-06-30 Q2 2024 | 2023-12-31 Q4 2023 | 2023-06-30 Q2 2023 | 2022-12-31 Q4 2022 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $404,394 | $258,075 | $0 | $359,658 | $477,006 | $762,608 | $1.4M | $2.5M |
| Gross Margin | -160.1% | -350.2% | 0% | 96.7% | -29.2% | -108% | -197.9% | -112.1% |
| Operating Margin | -1,191.5% | -1,445% | 0% | -564.3% | -493.2% | -554.7% | -424.3% | -410% |
| Net Income | $-6.2M | $-44.8M | $-815,000 | $-1.4M | $-2.7M | $-26.4M | $-5.9M | $-9.1M |
| Diluted EPS | -11.8 | -655.12 | -41.24 | -49.2 | -355.2 | -1,876,264 | -7,293.96 | -13,084 |
| Operating Cash Flow | $-3.2M | $-6.4M | $-375,604 | $-1.4M | $-2.6M | $-589,090 | $-911,484 | $-3.1M |
研究材料
Filing 摘要
电话会纪要摘要
暂无纪要摘要。